首页 > 市场调查报告书 > 医疗设备

药物递输设备 DDS

市场调查报告书

商品编码

1560787

全球鼻内给药市场 - 2024 - 2031

Global Intranasal Drug Delivery Market - 2024 - 2031

出版日期: 2024年09月23日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

2023年，全球鼻内给药市场达112亿美元，预计到2031年将达到207亿美元，2024-2031年预测期间复合年增长率为8.0%。

鼻内给药是一种经由鼻腔给药的方法。此途径利用鼻黏膜丰富的血管，使药物绕过胃肠道和肝臟的首过代谢，直接吸收到血液中。

它为输送各种药物提供了一种非侵入性且方便的替代方案，包括全身药物、疫苗以及针对鼻塞和过敏等局部病症的治疗。快速吸收和起效使得鼻内给药特别适用于需要快速缓解的病症，例如偏头痛和疼痛。

市场动态：

驱动程式和限制

对非侵入性给药方法的偏好日益增加

全球鼻内给药市场受到对非侵入性方法日益增长的偏好的推动，这些方法提供快速起效和便利性。这种方法对于需要快速吸收的药物特别有益，例如在紧急情况下或治疗中枢神经系统疾病。鼻内给药的便利性和患者依从性的提高也促进了其采用，特别是在口服或註射形式有困难的人群中，例如儿科和老年患者。

例如，2024 年 7 月，德州大学医学分部的研究人员最近发现，在对抗阿兹海默症和失智症等神经退化性疾病方面取得了重大进展。这项发表在《科学转化医学》杂誌上的研究介绍了一种创新的鼻喷雾疗法，该疗法在清除有害tau 蛋白积聚和改善患有神经退化性疾病的老年小鼠模型的认知功能方面显示出良好的效果。

吸收有限

由于局部刺激和鼻黏膜吸收有限，全球鼻内给药市场面临挑战。由于鼻腔解剖结构和黏液纤毛清除率的原因，某些药物可能会引起不适和吸收不一致。这些挑战限制了需要精确剂量和一致吸收的药物鼻内给药的有效性和接受度。

细分市场分析

全球鼻内给药市场根据类型、容器类型、应用、配销通路和地区进行细分。

此类型细分市场的鼻喷雾剂约占鼻内给药市场份额的43.3%

鼻喷剂型段约占43.3%。鼻喷雾剂是鼻内给药市场上施用各种药物的流行方法。它们将细小的药物雾直接输送到鼻腔中，以便快速吸收到血液中。这对于偏头痛、鼻塞和过敏性鼻炎等速效药物以及阿片类药物过量等紧急情况特别有用。鼻喷剂非侵入性且易于使用，使其成为注射或口服药物的首选替代品。

例如，2023年10月，新一代鼻喷剂Otrivin Nasal Mist上市，为因感冒、过敏性鼻炎、鼻窦炎而鼻塞的人带来更大的舒适感和易用性。这项创新技术由消费者健康公司 Haleon 和 Aptar Pharma 共同开发，采用新的微滴技术，喷出饱满而温和的雾气，均匀覆盖发炎区域，不会滴落到鼻子和喉咙后部。

市场地域占有率

预计北美在整个预测期内将占据总市场份额的 38.4% 左右

由于意识的提高和医疗保健设施的改善，预计北美在整个预测期内将占据约 38.4% 的总市场份额。政府措施和有利的报销政策也促进了这一增长。亚洲预计将经历高速成长，其中中国和印度由于大量投资、人口增长和政府资助而占据主导地位。

例如，2024 年 4 月，Amneal Pharmaceuticals 宣布在 FDA 批准后推出其非处方盐酸纳洛酮 (Naloxone HCI) 鼻喷雾剂，USP，4 毫克。这种通用等效药物在美国製造，用于治疗海洛因、芬太尼和处方阿片类药物等鸦片类药物的药物过量。 FDA 已批准该药物。

It offers a non-invasive and convenient alternative for delivering various medications, including systemic drugs, vaccines, and treatments for local conditions like nasal congestion and allergies. The rapid absorption and onset of action make intranasal drug delivery particularly useful for conditions that require quick relief, such as migraines and pain.

Market Dynamics: Drivers & Restraints

Increasing preference for non-invasive drug administration methods

The global intranasal drug delivery market is driven by the growing preference for non-invasive methods, offering quick onset of action and convenience. This method is particularly beneficial for drugs requiring rapid absorption, such as in emergency settings or treating central nervous system disorders. The convenience and improved patient compliance of intranasal delivery are also boosting its adoption, especially among populations with difficulty with oral or injectable forms, such as pediatric and geriatric patients.

For instance, in July 2024, researchers at the University of Texas Medical Branch recently discovered a significant advancement in the fight against neurodegenerative diseases such as Alzheimer's disease and dementia. The study, published in Science Translational Medicine, introduces an innovative nasal spray treatment that has shown promising results in clearing harmful tau protein build-up and improving cognitive functions in aged mice models with neurodegenerative diseases.

Limited absorption

The global intranasal drug delivery market faces challenges due to local irritation and limited absorption through the nasal mucosa. Certain drugs can cause discomfort and inconsistent absorption due to nasal anatomy and mucociliary clearance rates. These challenges limit the effectiveness and acceptance of intranasal drug delivery for medications requiring precise dosing and consistent absorption.

Market Segment Analysis

The global intranasal drug delivery market is segmented based on type, container type, application, distribution channel, and region.

The nasal spray from the type segment accounted for approximately 43.3% of the intranasal drug delivery market share

The nasal spray from the type segment accounted for approximately 43.3%. Nasal sprays are a popular method for administering various medications in the intranasal drug delivery market. They deliver a fine mist of medication directly into the nasal cavity, allowing rapid absorption into the bloodstream. This is particularly useful for quick-onset drugs like migraines, nasal congestion, and allergic rhinitis, as well as emergencies like opioid overdose. Nasal sprays are non-invasive and easy to use, making them a preferred alternative to injections or oral medications.

For instance, in October 2023, Otrivin Nasal Mist, a new generation of nasal spray, was launched to bring greater comfort and ease of use to people suffering from nasal congestion due to colds, allergic rhinitis, and sinusitis. The innovation, developed by consumer health company Haleon and Aptar Pharma, uses new microdroplet technology to dispense a full but gentle mist that evenly covers inflamed areas, with no dripping at the back of the nose and throat.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increased awareness and improved healthcare facilities. Government initiatives and favorable reimbursement policies are also contributing to this growth. Asia is expected to experience high growth, with China and India dominating due to large investments, a rising population, and government funding.

For instance, in April 2024, Amneal Pharmaceuticals announced the availability of its Over-the-Counter Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following FDA approval. This generic equivalent is manufactured in the U.S. and is used to treat drug overdose from opioids like heroin, fentanyl, and prescription opioid medications. The FDA has approved the medication.

Market Segmentation

By Type

Nasal Spray

Nasal Drops

Nasal Gel

Nasal Powder

By Container Type

Pressurized Container

Non-pressurized Container

By Application

Allergic and Non-allergic Rhinitis

Nasal Congestion

Sinusitis

Asthma

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include AstraZeneca, Baxter International, Inc., Becton, Dickinson, and Company, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer Inc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc, Aegis Therapeutics LLC among others.

Key Developments

In November 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, just announced an expansion of its nasal drug delivery capabilities by adding a family of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal drug delivery is a good alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action.

Why Purchase the Report?

To visualize the global intranasal drug delivery market segmentation based on type, container type, application, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the intranasal drug delivery market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global intranasal drug delivery market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Container Type
3.3. Snippet by Application
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing preference for non-invasive drug administration methods
  - 4.1.1.2. Rise in the prevalence of chronic diseases
- 4.1.2. Restraints
  - 4.1.2.1. Limited absorption
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 6.1.2. Market Attractiveness Index, By Type
6.2. Nasal Spray*
- 6.2.1. Introduction
6.3. Nasal Drops
6.4. Nasal Gel
6.5. Nasal Powder

7. By Container Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
7.2. Market Attractiveness Index, By Container Type
7.3. Pressurized Container*
- 7.3.1. Introduction
- 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Non-pressurized Container

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Allergic and Non-allergic Rhinitis*
- 8.2.1. Introduction
8.3. Nasal Congestion
8.4. Sinusitis
8.5. Asthma
8.6. Others

9. By Distribution Channel

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. The U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. UK
  - 10.3.7.3. France
  - 10.3.7.4. Italy
  - 10.3.7.5. Spain
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. AstraZeneca*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Baxter International, Inc
12.3. Becton, Dickinson, and Company
12.4. GlaxoSmithKline PLC
12.5. Johnson & Johnson
12.6. Novartis AG
12.7. Pfizer Inc
12.8. Valeant Pharmaceuticals International, Inc
12.9. Merck & Co., Inc
12.10. Aegis Therapeutics LLC (*LIST NOT EXHAUSTIVE)